Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Psoriasis and Comorbidities: Advances in Therapy
Description
The presentation addresses the complexities of psoriasis, emphasizing its various forms and associated comorbidities, including arthritis, cardiovascular diseases, metabolic syndrome, and mental health disorders such as anxiety and depression. Psoriasis affects around 60 to 125 million people globally, with significant geographic variations in prevalence. The speaker highlights the multifaceted nature of psoriasis, including genetic and environmental factors, and stresses the importance of recognizing psoriasis as a systemic disease rather than just a skin condition. Effective management of psoriasis is shown to greatly influence the patient’s overall health and quality of life, particularly in preventing comorbidities by promoting timely interventions and proper treatment adherence. The discussion also delves into the significant role of obesity as both a comorbidity and a trigger for psoriasis, noting its impact on treatment outcomes. Insights into mental health implications and gender disparities in depressive symptoms among psoriasis patients are presented alongside the need for interdisciplinary collaboration among healthcare providers. Recent treatment guidelines underscore the importance of integrating systemic therapies and biologics appropriately. The speaker concludes by inviting collaboration for a global healthcare study aimed at improving psoriasis care standards and addressing treatment gaps across different countries.
View moreConclusions
- Psoriasis is a complex, chronic inflammatory disease that affects millions of people worldwide.
- Psoriasis is associated with several comorbidities, including cardiovascular diseases, metabolic syndrome, and psychiatric disorders.
- Early identification and management of comorbidities in psoriasis patients can improve their overall health outcomes and treatment responses.
- Patients with psoriasis experience a significant physical, emotional, and social burden due to their disease and its comorbidities.
- Obesity is a significant risk factor associated with both psoriasis and its comorbidities, reducing treatment efficacy and exacerbating disease severity.
- Psychiatric comorbidities, such as anxiety and depression, are prevalent among psoriasis patients, especially in women and during pregnancy.
- Interdisciplinary cooperation among healthcare providers is essential for the effective management of psoriasis and its comorbidities.
- Regular screening for comorbidities is vital for dermatologists managing psoriasis patients.
- Patient education and self-responsibility are crucial components in managing psoriasis effectively.
- New treatment guidelines emphasize the importance of targeted therapies in managing psoriasis and its associated conditions.
- Maul JT et al. JEADV 2018
- Griffiths et al. 2007
- Parisi et al. 2020
- Augustin et al. 2010
- Mrowietz U et al. Exp Dermatol. 2014;23:705-709
- Kimball AB et al. J Eur Acad Dermatol Venereol 2011; 25(2): 246
- Afonina IS et al. Cell Mol Life Sci. 2021;78:2709-2727
- Elmets CA et al. J Am Acad Dermatol. 2019;80:1073-1113
- Menter A et al. Semin Cutan Med Surg. 2018;37(suppl 2):S49-S52
- Armstrong AW, Read C. JAMA. 2020;323:1945-1960
- Pinter et al. Dermatol Ther. 2020, modified
- Boehncke et al. BMJ 340:b5666, 2010
- Naldi L et al. Dermatology 217:365-373, 2008
- Dowlatshahi EA et al. J Invest Dermatol 2014, 134:1542-51
- Shelton R, Miller AH. Dialogues Clin Neurosci 2011; 13:41-53
- Kumar B et al. Indian J Dermatol Venereol Leprol 77:625, 2011
- Bilgic A et al. Pediatr Dermatol 27:614-617, 2010
- Kurd SK et al. Arch Dermatol 146:891-895, 2010
- Dowlatshahi EA et al. Acta Derm Venereol 93:544-550, 2013
- McDonough E et al. J Rheumatol. 2014;41(5):887-896
- Bandoli G et al. Br J Dermatol. 2010;163(2):334-349
- Rodriguez-Zuniga et al. JAAD, 2017; 77:657-66
- Nast A et al. JEADV 2020